12 registrations that name inositol as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 12 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 12 registrations
RecruitingNCT06575868
Myo-inositol During Pregnancy to Prevent Gestational Diabetes
No phase
Tufts Medical Center
About 40 people
Started Mar 1, 2025
In plain words A study of inositol in female participants 18 to 45, run by Tufts Medical Center. It plans to enroll about 40 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 45. Conditions: Pregnancy Related.
What it tests, as registered
Myo-inositol; Myo-inositol placebo
Registered summary
Myoinositol is an insulin-like compound that is present in both plant and animal cells. Humans synthesize it naturally, but it is also obtained in our diet. It works through an intracellular signaling pathway to increase insulin sensitivity. Myoinositol has been used as an over-the-counter (OTC) supplement in the management of polycystic ovarian syndrome due to this effect. Myoinositol has also been shown to improve glycemic profiles in pregnant euglycemic women and well as improve insulin sensitivity in pregnant patients with gestational diabetes mellitus (GDM). The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT03059173
Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome
Phase 3
University Hospital, Lille
About 276 people
Started Sep 12, 2023
In plain words A Phase 3 study of inositol in female participants 18 to 35, run by University Hospital, Lille. It plans to enroll about 276 people at 1 site, none in the US.
Having PCOS defined by the Rotterdam criteria: high antral follicle count (AFC) (> 19 per ovary) and/or a disorder of the cycle and/or hyperandrogenism (at least two of the three criteria),
Having never been treated with CC (or previous treatment with CC interrupted for > 3 months).
Having received complete information and having signed consent.
1 more inclusion criterion and the exclusion criteria are on the listing.
The main objective will be to check if MyoInositol (MYO) reduces the total resistance rate to Clomiphene Citrate (CC). For this, our study will be controlled, randomized and double blinded. It will include patients with PCOS (polycystic ovary syndrome, defined by the Rotterdam criteria) who wish to become pregnant and are eligible to simple ovulation induction by CC. Half of them will receive MYO + levomefolic acid (5-MTHF) in addition to the CC, while the other half will receive a placebo containing only 5-MTHF in addition to the CC. The full summary is on the listing.
Where, as registered
No US site; France (1).
RecruitingNCT07241221
Antenatal Myo-inositol Supplementation in Pre-existing Diabetes
No phase
National University Hospital, Singapore
About 182 people
Starts Dec 2025 (estimated)
In plain words A study of inositol in female participants 21 to 45, run by National University Hospital, Singapore. It plans to enroll about 182 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 21 to 45. Conditions: Perinatal and Neonatal Outcomes in Pregnancies With Type 2 Diabetes Mellitus (T2DM).
Pregnant women aged 21 years to 45 years old at the time of recruitment
Ongoing, viable, singleton intrauterine pregnancy
Between 12+0 days-16+6 days weeks' gestation at recruitment
T2DM diagnosed by a documented 75g Oral Glucose Tolerance Test (OGTT) showing a fasting glucose of >7 mmol/L or 2h glucose >11.1 mmol/L, or an HbA1C >6.5%, either prior to pregnancy or during the first 16 weeks of the index pregnancy
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Myo-inositol and folic acid supplement; Folic acid supplement
Registered summary
This feasibility pilot study aims to gather data that can guide the design of a larger, more comprehensive trial to establish the effects of myo-inositol supplementation on supporting healthy outcomes in pregnancies complicated by Type 2 Diabetes Mellitus (T2DM). It seeks to assess myo-inositol's potential to support fetal and neonatal health, and optimise maternity outcomes as a complementary approach and adjuvant to existing diabetes mellitus therapies, as well as investigate the underlying biological mechanisms.
Where, as registered
No US site; Singapore (1).
RecruitingNCT07630779
Efficacy of Alpha Lipoic Acid Combined With Myo-Inositol in Non-Diabetic PCOS Patients
Phase 3
Beni-Suef University
About 180 people
Started Mar 10, 2026
In plain words A Phase 3 study of inositol in female participants 21 to 40, run by Beni-Suef University. It plans to enroll about 180 people at 1 site, none in the US.
This study evaluates the efficacy of alpha-lipoic acid combined with myo-inositol, with or without metformin, in improving menstrual regularity and ovulation in non-diabetic women with polycystic ovary syndrome (PCOS). The study also assesses metabolic, hormonal, and clinical outcomes.
Where, as registered
No US site; Egypt (1).
RecruitingNCT07256769
Vitamin k, D-chiro Inositol and α-lactalbumin in Bone Homeostasis
Observational
Regina Elena Cancer Institute
About 134 people
Started Sep 29, 2025
In plain words An observational study of inositol in female participants 35 to 70, run by Regina Elena Cancer Institute. It plans to enroll about 134 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 35 to 70. Conditions: Osteoporosis Secondary; Breast Cancer Females.
caucasian women aged between 35 and 70;
diagnosed with breast cancer undergoing treatment with aromatase inhibitors or tamoxifen + GnRH analogues or aromatase inhibitors + GnRH analogues not started more than 12 months ago, about to start treatment with oral bone resorption…
vitamin D levels below 30 ng/ml (test carried out no more than 6 months prior to the baseline/T0 visit)
patients able to comply with the procedures and/or requirements of the study
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Group 1: calcium carbonate/cholecalciferol; Group 2: Synostea® (calcium carbonate/cholecalciferol/vitamin K/α-lactalbumin/ d-chiro-inositol)
Registered summary
In women with breast cancer undergoing adjuvant hormone therapy, the marked tissue hypoestrogenism induced by therapy with aromatase inhibitors and/or tamoxifen ± GnRH analogues causes a significant acceleration in bone mass loss, with a consequent increased risk of fracture from the first year of therapy. It is therefore essential to start treatment with antiresorptive drugs and calcium and vitamin D supplementation. It has been hypothesized that vitamin K and α-lactalbumin have an effect in improving the absorption of calcium and vitamin D. The full summary is on the listing.
Where, as registered
No US site; Italy (2).
RecruitingNCT05448365
Vitamin D, Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in Uterine Fibroid
No phase
Lo.Li.Pharma s.r.l
About 60 people
Started Jul 1, 2022
In plain words A study of inositol in female participants 30 to 40, run by Lo.Li.Pharma s.r.l. It plans to enroll about 60 people at 2 sites, none in the US.
The study will evaluate the impact on uterine fibroids' volume of a combination of natural molecules including Epigallocatechin gallate, Vitamin D, D-chiro-inositol and Vitamin B6. The patients will be evaluated at baseline and after three months of treatment with placebo or product.
Where, as registered
No US site; Italy (2).
RecruitingNCT07685015
The Impact of Myo-Inositol on Glycemic Control and Oxidative Stress in Gestational Diabetes Mellitus
No phase
Medical University of Vienna
About 40 people
Started Mar 23, 2026
In plain words A study of inositol in female participants 18 to 45, run by Medical University of Vienna. It plans to enroll about 40 people at 2 sites, none in the US.
The purpose of this clinical study is to investigate the potential effects of myo-inositol supplementation on changes in glycemic control parameters, oxidative stress, inflammatory biomarkers, psychometric markers, and body composition in participants with gestational diabetes mellitus (GDM). The study duration is 3 to 3.5 months, depending on the time of GDM diagnosis. Before the active phase begins, there is a 10-day observation period during which participants' blood glucose levels are monitored using a continuous glucose monitoring device. The full summary is on the listing.
Where, as registered
No US site; Austria (2).
RecruitingNCT06736015
Myo-inositol and Selenium in Indeterminate Thyroid Nodules (TIR3a)
No phase
Regina Elena Cancer Institute
About 30 people
Started Oct 23, 2024
In plain words A study of inositol in people 18 and older, run by Regina Elena Cancer Institute. It plans to enroll about 30 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Thyroid Nodule.
Adult (>18 years old),
both sexes,
patients presenting thyroid nodules classified as TIR 3A, based on cytological evaluation on sample from the first fine needle aspiration (FNA),
written Informed consent,
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Myo-Inositol 600 mg + Selenium 83 mcg
Registered summary
Thyroid nodules present a variable risk of malignancy depending on the cytological result obtained from the ultrasound-assisted thyroid fine needle aspiration biopsy. According to the Italian Cytology classification SIAPEC-IAP 2014, the TIR3A nodules are indeterminate nodules with a risk of malignancy lower than 10%. Clinical and instrumental follow-up is recommended in these cases, including repetition of the fine needle aspiration. The full summary is on the listing.
Where, as registered
No US site; Italy (1).
Not yet recruitingNCT06840613
Glucophage Plus Myo-Inositol vs Glucophage in Glycemic Control Among Patients With Gestational Diabetes Mellitus
No phase
University of Health Sciences Lahore
About 90 people
Starts Mar 2025 (estimated)
In plain words A study of inositol in female participants 18 to 35, run by University of Health Sciences Lahore. It plans to enroll about 90 people and lists no sites yet.
GDM diagnosed during pregnancy as per operational definition
22 to 32 weeks of gestation
No more than 35 days after GDM diagnosis
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Myo-Inositol; Glucophage
Registered summary
This randomized controlled trial aims to compare the efficacy of Glucophage plus Myo-Inositol versus Glucophage alone in glycemic control among patients with gestational diabetes mellitus (GDM). The study will assess whether the addition of Myo-Inositol improves glycemic control and reduces insulin requirements in GDM patients. Participants will be randomized into two groups: one receiving Myo-Inositol in combination with Glucophage and the other receiving Glucophage alone. The primary outcome will be glycemic control as assessed by fasting and postprandial glucose levels. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07629895
Myo-Inositol Alone Versus Myo-Inositol Plus Alpha-Lactalbumin in Women With Polycystic Ovary Syndrome
No phase
Quaid-e-Azam Medical College
About 82 people
Starts Sep 2026 (estimated)
In plain words A study of inositol in female participants 18 to 35, run by Quaid-e-Azam Medical College. It plans to enroll about 82 people at 1 site, none in the US.
Diagnosed with polycystic ovary syndrome according to Rotterdam criteria.
Diagnosis of PCOS for at least 6 months before enrollment.
Willing to conceive.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Myo-inositol; Alpha-Lactalbumin
Registered summary
Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting reproductive-aged women and is associated with menstrual irregularities, infertility, hyperandrogenism, obesity, and insulin resistance. Myo-inositol is commonly used as an insulin-sensitizing agent to improve reproductive and metabolic outcomes in women with PCOS. Alpha-lactalbumin may enhance the intestinal absorption and bioavailability of myo-inositol and potentially improve treatment response. The full summary is on the listing.
Where, as registered
No US site; Pakistan (1).
Not yet recruitingNCT03585738
Effects of Oral Inositol Supplementation on Obstetrics Outcomes in PCOS Women
No phase
Università degli Studi dell'Insubria
About 80 people
Starts Jan 1, 2022 (estimated)
In plain words A study of inositol in female participants 18 to 40, run by Università degli Studi dell'Insubria. It plans to enroll about 80 people and lists no sites yet.
Pregnancy spontaneously conceived in women with PCOS diagnosed by Rotterdam criteria that starts oral supplementation before conception.
The exclusion criteria are on the listing.
What it tests, as registered
Inositol + Folic acid; Folic acid
Registered summary
Polycystic ovarian syndrome (PCOS) is a heterogeneous, multifaceted and complex disorder characterized by insulin resistance (IR), hyperinsulinemia, and hyperandrogenism leading ovarian disfunction and infertility. Given the central pathogenic role of IR in the endocrine, reproductive, and metabolic disturbances of PCOS, several pharmacological and non-pharmacological approaches have been proposed to counteract the hyper insulinemic IR typical of the syndrome. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07584772
Use of D-Chiro-inositol in Male Functional Hypogonadism Associated With Sexual Dysfunction
No phase
Cardarelli Hospital
About 35 people
Starts Jul 1, 2026 (estimated)
In plain words A study of inositol in male participants 50 to 75, run by Cardarelli Hospital. It plans to enroll about 35 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists male participants 50 to 75. Conditions: Functional Hypogonadism.
Men aged between 50 and 75
Affected by functional hypogonadism associated with male aging
The exclusion criteria are on the listing.
What it tests, as registered
D-chiro-inositol
Registered summary
A prospective, uncontrolled, non-pharmacological interventional study conducted on men with functional or borderline hypogonadism, aimed at evaluating, after 3 months of supplementation with D-Chiro-inositol, changes in hormonal profile and sexual function.